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Reinhold Graf, Dirk Boehmer, Jacek Nadobny, Volker Budach and Peter Wust*Abstract
Background: Interfraction prostate motion must be compensated by increased safety margins. If filling status of
rectum and bladder is constant, motion should be reduced. We attempted to reduce interfraction motion errors by
proper patient instruction.
Method: In 38 patients pairs of radio-opaque fiducial markers were implanted prior to definitive radiotherapy.
Patients were positioned either according to skin marks or infrared body marker. We measured prostate
displacement, i.e. pelvic bones versus intraprostatic marker position, via ExacTrac (two orthogonal radiographies)
in 1252 fractions. Systematic and random setup and displacement errors were determined and safety
margins estimated.
Results: In our study interfraction prostate displacement is < 1 mm in RL direction, and < 2 mm in AP and SI
direction. Systematic errors are slightly below random errors (< 1.5 mm). Positioning according skin marks results
in higher inaccuracies of ±1.5 – 2 mm in RL and ±2 – 2.5 mm in AP/SI direction.
Conclusions: In case of appropriate patient instructions (constant organ filling) the positioning via bone fusion
requires CTV-PTV margins of 2 mm in RL, 4 mm in AP, and 5 mm in SI direction. Studies without any description of
patient instruction found much higher margins of > 1 cm in AP and SI direction.
Keywords: Patient instruction, Fiducial markers, Prostate motionIntroduction
The dose–response relationship between long-term PSA
control and radiation dose in the prostate is beyond con-
troversy and validated by numerous studies and analyses,
among them several randomized trials [1,2]. A minimum
dose of 72 Gy (conventional fractionation) is required
[3], but higher doses are desirable and further increase
the rate and duration of PSA control. However, further
increasing the dose towards 80 Gy elevates the dose in
parts of the rectum and might be associated with late
rectal toxicity [4].
The radiation exposure of the normal tissues sur-
rounding the prostate, in particular the rectum, is mainly
determined by the CTV – PTV safety margins. These
margins can be influenced by the positioning technique
of the patient and all measures to cover the CTV with
the prescribed dose as accurate as possible.* Correspondence: peter.wust@charite.de
Department of Radiation Oncology, Charité Universitätsmedizin Berlin,
Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany
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reproduction in any medium, provided the orTwo major sources of uncertainty have been identified.
Firstly, setup errors describe the variation of bony land-
marks relative to skin marks, utilizing either laser
crosses or infrared body markers. These errors depend
on the diligence of the patient positioning (using certain
positioning devices), the setup-procedure and in particu-
lar of the patient´s habitus. Employing modern image
guidance such as portal images [5], MV-CT [6] or cone-
beam CT [7] in conjunction with bone fusion this kind
of set-up error can be minimized. Secondly, prostate
motion relative to the pelvic bones is the remaining and
dominant error source with variations of the prostate
position either between fractions (interfraction) or dur-
ing the irradiation (intrafraction). In order to correct the
isocentre with respect to these displacements intrapro-
static implanted markers are used, in particular metallic
markers (gold, titanium). Marker based corrections have
shown in numerous studies (see discussion), that the un-
certainties caused by the prostate movement might be
significant requiring safety margins > 1 cm. These errors. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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should be reduced. Therefore, most investigators recom-
mend the use of intraprostatic markers to track the
prostate in order to reduce safety margins.
Prostate position or displacement depend on organ
filling or distension, in particular of the rectum and to a
minor degree of the bladder. Theoretically, prostate dis-
placement can be reduced and is possibly less important,
if a constant and reproducible organ filling is main-
tained. A well-defined reference situation might be an
empty rectum and a bladder filled with a given content
of some hundred millilitres. Some authors mention this
reference filling state, but often this patient-dependent
factor is not specified. Elaborated examinations about
the relationship between patient preparation and pros-
tate displacement are missing to our knowledge, and
marker implantation is recommended.
However under clinical conditions, marker implant-
ation is not only an additional invasive procedure (with
some additional risk), but also time-consuming and ex-
pensive. Therefore, the question is reasonable if prostate
motion can be reduced (and to which extent) by appro-
priate patient education. In the present study interfrac-
tional prostate motion has been investigated for a
patient group, which has been carefully trained to keep
the organ filling constant.
Patients and methods
From 2005 – 2010 we offered patients with prostate car-
cinoma a definitive radiotherapy with an additional
marker-based image guidance. All patients were irra-
diated by intensity-modulated radiotherapy technique
(IMRT) at the dedicated stereotactic linear accelerator
NovalisTM (Brainlab AG, Feldkirchen, Germany) adjust-
ing the setup by the ExacTrac/Novalis Body (ETNB) X-
ray positioning system. On a routine basis an automatic
bone fusion of the two non-coplanar oblique isocentric
(stereoscopic) kV X-ray images with the corresponding
digitally reconstructed radiographs (DRR) was executed.
After marker implantation the correct setup (reference
position) with respect to the prostate is achieved by
manual fusion of the four marker end points adjusting
the ETNB radiographs with the DRR. The marker end
points have been specified in the planning CT during
contouring of target volumes and normal tissues.
A total of 38 patients gave their informed consent to
the marker implantation. We used either two stranded
pairs of inactive marker seeds (until 2007, IsocordTM,
Eckert & Ziegler, Berlin, Germany) and later on two
VisiCoilTM gold markers (Radiomed Corp Tyngsboro,
MA, USA) with a length of 3 cm. The implantation was
performed during a laparoscopic pelvic lymph node ex-
ploration without additional burden or during a minimal-
invasive procedure via puncture through the perineum inlocal anaesthesia employing ultrasound and X-ray guid-
ance. No grade 2 or higher complications were observed
during/after the marker implantations.
For every patient, the planning CT was acquired in
treatment position (head and neck support, knee and
feet support) after a special patient instruction and prep-
aration. The objective of this programme is a constant
and reproducible filling of rectum and bladder, i.e. a rec-
tum as empty as possible and a bladder filled with ap-
proximately 200–300 ml fluid. In detail, information
sheets were handed out to patients with instructions on
how to avoid flatulent food, too many fibres, and to
empty the rectum prior to the planning CT and every
single radiotherapy fraction. In addition, prior to the
planning CT an enema was applied. Patients are trained
on how to fill the bladder prior to CT and radiotherapy
by drinking and how to adapt the amount of fluid to the
required volume (measured in the planning CT) depend-
ing on the actual volumes registered after every radio-
therapy session in a special measuring container.
At first the patient is positioned in treatment position
according to skin marks or infrared markers. Then the
ETNB radiographs are shot, the automatic bone fusion
is accomplished and the setup is corrected according to
the skeleton. In a second step a manual fusion with re-
spect to the gold markers head and bottom is conducted.
The correcting vector describes the prostate motion
(displacement relative to the pelvic bone). These prostate
displacements in three axes (left-right, superior-inferior,
anterior-posterior) were determined in 1252 fractions. In
addition, we registered the correcting vectors either
from the skin marks (270 fractions) or the infrared mar-
kers (247 fractions) to the internal markers for a sub-
group of patients to get an impression of the setup
errors arising from conventional positioning procedures.
The systematic error
P
of the whole sample is the
standard deviation of the means of displacements per
patient. The random error σ is defined as standard devi-
ation of all displacements of the whole sample. From the
systematic and random errors the required safety mar-
gins can be estimated according to statistical considera-
tions [8]. We used the formula 2.5
P
+ 0.7 σ to assess
the margin.
Results
The recommendations to keep the filling of rectum and
bladder constant were accepted by all patients. Most
patients demanded an exact timing of the radiotherapy
session to achieve the reference volume in the bladder.
The bladder size measured in the planning CT was com-
municated to the patient. Some discomfort arose from
delays of the irradiation procedure, which is under clin-
ical conditions sometimes inevitable. In consequence,
patients assessed the desired bladder volume as difficult
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of the rectum) was estimated as easier because of
increased stool frequency caused by mucosa irritation
in most patients.
Systematic and random translational errors for the dif-
ferent setup procedures with respect to the marker-based
reference positions are listed in Table 1. The lowest ru-
bric (bone fusion) shows the prostate motion relative to
the pelvic bone. As to expect the displacements aver-
aged over all 1252 samples are near to zero (0.15 in LR,
-0.64 in SI, -0.18 in AP direction). In our study with
careful patient instruction and efforts the derived CTV-
PTV margins are < 2 mm in lateral, and < 5 mm in the
other directions.
The positioning errors are clearly higher if the patients
are aligned on the treatment table according to the laser
crosses at the skin (see the upper rubric in table 1).
Here, CTV-PTV margins of up to 8 mm are required.
Interestingly, margins by use of infrared body marker
(middle rubric) are small and of similar magnitude as
the margins caused by prostate motion, at least for the
AP and SI directions. Errors to the lateral directions are,
however, higher by using body markers and require mar-
gins of 5 mm.
Discussion
Radiotherapy technology has further evolved during the
last years. While the improvement of dose distributions
by using IMRT is common since 1995 now the next
technological step IGRT (image guided radiotherapy) is
approaching routine use. IGRT basically increases theTable 1 Systematic and random translational errors for
conventional positioning with skin marks (laser crosses),
infrared body markers and bone fusion (via ExacTrac/
Novalis Body X-ray system=ETNB) by using the marker-
based prostate position as “correct” reference position
Setup LR error [mm] SI error [mm] AP error [mm]
Skin marks
Σ 1.56 2.46 1.87
σ 1.82 2.31 2.51
Margin 5.17 7.76 6.43
Infrared markers
Σ 1.35 0.75 0.96
σ 1.73 1.10 1.71
Margin 4.59 2.64 3.60
Bone fusion (ETNB)
Σ 0.53 1.38 1.10
σ 0.75 1.84 1.79
Margin 1.85 4.74 4.00
The recommended safety margins according to the formula of van Herk
(margin = 2.5
P
+ 0.7 σ, see text) along the three axes are given in the
third line.therapeutic ratio by reduction of the PTV, i.e. the
CTV – PTV safety margin. In this way, either the sur-
rounding tissues can be better spared or the dose in the
prostate can be further escalated. However, no prospective
randomized study has been conducted until now to valid-
ate that relevant clinical endpoints such as PSA-control
and/or late toxicity are unequivocally improved by IGRT.
Conversely, even some studies indicate that uncritical use
of IGRT can impair PSA control. Heemsbergen et al. 2007
[9] found a loss of PSA control of the patient group with
higher rectum extension during planning CT, but they
had reduced the PTV and relied on bone fusion without
intraprostatic markers and/or appropriate patient prepar-
ation regarding rectum filling. Interestingly, the reduced
PSA control was only seen in the subgroup of patients
with high risk of seminal vesicles involvement. Engels
et al. 2009 [10] described a negative prognostic impact of
a distended rectum on PSA control even in case of
marker-based image guiding techniques, but again without
documented patient education. In contrast, for a suffi-
ciently sophisticated prostate tracking via ultrasound the
outcome did not depend on rectum filling during planning
CT [11]. On summary, IGRT guarantees not automatically
better clinical results and an elaborated analysis how to
use IGRT is desirable.
It is evident that precision of prostate cancer radio-
therapy can be enhanced by daily positioning control
[12]. In order to reduce the geographic miss of the pros-
tate fiducial intraprostatic markers are generally recom-
mended. In several studies [8,13,14] large errors by
interfractional prostate motion were found as summar-
ized in Table 2. The LR displacements are consistently
small, and the AP displacements are typically dominant.
The SI displacements are in between, but can approach
magnitudes near the AP movements. Authors explain
the dominance of the AP direction with the variable fill-
ing of the rectum, and in fact sometimes found a bias of
the ventral orientation. The variable rectum filling
appears as major hindrance to further reduce the PTV.
If in marker-based studies displacements of prostate
movements were investigated, different conclusions are
possible. Most investigators recommend marker im-
plantation to eliminate these errors caused by motion,
but do not trouble much about the causes of these varia-
tions. In the present study we attempted to reduce pros-
tate movements by keeping the organ filling as constant
as possible by careful patient instructions – and to verify
this reduction by measurements. Interestingly, patient
instructions regarding the bowel are not mentioned in
the other studies listed in Table 2 (right row) even
though this appears to warrant additional accuracy dur-
ing radiotherapy administration.
Our comparisons in Table 2 and 3 indicate that
motion-induced errors might in fact be considerably
Table 2 Systematic and random translational errors attributed to interfractional prostate motion (see Table 1) for a
selection of studies (lines 2–4) in comparison to residual errors (line 5: estimated by the deviations between two










Current study Interfraction motion
P
= σ = 0.5 0.7 1.4 1.8 1.1 1.8 Bowel instructions
van Herk 2004 [8] Interfraction motion
P
= σ = 0.9 0.9 1.7 1.7 2.7 2.7 Bowel instructions not mentioned
Soete et al. 2007 [13] Interfraction motion
P
= σ = 1.3 1.6 4.2 2.3 4.3 2.8 Bowel instructions not mentioned
Tanyi et al. 2010 [14] Interfraction motion
P
= σ= 0,5 0,4 2,9 2,3 3,4 2,5 Bowel instructions not mentioned
Tanyi et al 2010 Residual error
P
= σ = 0.6 1.4 0.6 1.4 0.5 1.6 CBCT vs. Calypso
Tanyi et al 2010 Intrafraction motion
P
= σ = 0.3 0.8 0.7 1.4 0.5 1.3 Calypso System
Σ = systematic error, σ = random error, LR = left-right, SI = superior-inferior, AP = anterior-posterior.
Table 3 Safety margins attributed to interfractional
prostate motion (see Table 1) calculated with the van












van Herk 2004 [8] Interfraction
motion
2.9 5.4 8.6
Soete et al 2007 [13] Interfraction
motion
4.4 12.1 12.7
Tanyi et al 2010 [14] Interfraction
motion
1.6 8.9 10.2
Tanyi et al 2010 Residual error 2.5 2.6 2.3
Tanyi et al 2010 Intrafraction
motion
2.8 3.7 3.2
LR = left-right, SI = superior-inferior, AP = anterior-posterior.
The results of the current study are compared with other published data (Σ =
systematic error, σ = ramdom error).
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the systematic errors in AP-direction are lowered by a
factor of 2–4, and in consequence the CTV-PTV mar-
gins are more than halved. Smitsmans et al. 2008 found
as well a trend of reduced interfraction prostate motion
by a dietary protocol [15].
Therefore, instructions to empty the rectum and fill
the bladder can at least partially replace marker based
tracking. It is on the other hand probable, that routine
use of intraprostatic markers can reduce setup errors,
but would not completely prevent inaccuracies [10]. This
has to be balanced with patient risk, patient burden and
additional time, effort and costs – and therefore the
overall benefit of marker based image guidance has to be
considered with care.
One major concern is migration of markers. In several
investigations inter-marker distances have been regis-
tered during a radiotherapy course [16]. The measured
variations of intermarker-distances are compatible with
zero. This is in agreement with a few checks we per-
formed during our study by repetitive CT-scans.
Nevertheless, a residual error is still expected for
marker-based localisation incorporating all remaining in-
accuracies such as geometric/mechanic uncertainties, ro-
tational errors and inaccuracies of the image processing.
This residual error can be estimated if two different
measurement methods are simultaneously adopted and
compared such as marker-based cone-beam CT (CBCT)
and a marker-based (transponder) electromagnetic local-
isation method (CalypsoW) [13]. Tables 2 and 3 (lines 5)
demonstrate that the residual errors and the derived
margins are only slightly below the errors and margins
of our study. The advantage is at maximum 2 mm in SI-
direction (2.6 instead of 4.7 mm).
Rapid intrafractional movements are additional
sources of errors, which are inevitabble and therefore a
limiting factor. The errors and resulting margins (lines 6
in Tables 2–3) are even higher than the residual errors
and approach the values in our study. Intrafraction mo-
tion of prostate has been investigated in various series[17], and the standard deviations are quite comparable
ranging around 1 mm in LR-direction and between 1 –
3 mm in SI or AP direction. The derived safety margins
are approximately 3 mm in all directions and appear as
a lower threshold. By statistical reasons the most import-
ant error components, i.e. inter-fraction and intra-
fraction motion, should be of comparable size.
Table 3 illustrates that margins induced by interfrac-
tion motion in conjunction with patient instructions
(line 1) and intrafraction motion (line 6) are close to-
gether with 1 mm or less difference. Under these cir-
cumstances the inter-fraction motion is the dominant
error source with a combined margin (estimated as the
root of the quadratic sum) 3.3 mm in LR, 6.0 mm in SI,
and 5.1 mm in AP direction. If we attempt to eliminate
the inter-fraction motion error by marker implantation
and marker-based localisation (CBCT or ExacTrac) a re-
sidual margin (line 5 in Table 3) will still remain and
add to the intra-fraction motion error. Then the com-
bined margin would be estimated as 3.8 mm in LR,
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our study the margin reduction caused by marker im-
plantation is only in the range of one millimetre. This is
in fact quite unspectacular and must be charged against
the disadvantages of marker implantation. If however
large variations of rectum content (lines 2–4, Table 3)
are tolerated, the required margins are clearly too large,
and marker-based image guidance appears inevitably.
Intrafraction motion can only be corrected by a
marker-based on-line tracking system e.g. the Cyber-
knife. However this leads to a completely different radio-
therapy schedule based on hypofractionation, which
should primarily be investigated in studies. It should be
noted that measures to reduce the interfraction motion
will also reduce the intrafraction motion, because in the
empty and relaxed intestine the peristalsis is reduced as
well. Therefore, the suggested margins might be even
too pessimistic.
Conclusions
Careful patient instruction in order to achieve a constant
anatomy (filling status of rectum and bladder) might be
a successful strategy to permit reasonably low safety
margins for IMRT/IGRT of prostate cancer. This pro-
cedure might be nearly as good as marker-based image
guidance. Further marker-based studies are needed to
specify the optimum strategy to minimize inter- and
intrafraction movement and to clarify the role of IGRT
technology to improve clinical outcome.
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